Pharmacyclics has earned a $50 million milestone payment from partner Johnson & Johnson after the European Medicines Agency accepted an application for the review of Imbruvica. Last week, the company earned a $60 million milestone fee from J&J subsidiary Janssen Biotech when the FDA approved Imbruvica for the treatment of mantle cell lymphoma.

Related Summaries